We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: MASH
MedXY News
EnglishTag

MASH

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Liver, Portal, and Systemic Thyroid Hormone Alterations in End-Stage MASH: Distinct Diagnostic and Prognostic Roles for T3/rT3 Ratio and T4
Clinical Updatesthyroid hormone metabolismResmetirom

Liver, Portal, and Systemic Thyroid Hormone Alterations in End-Stage MASH: Distinct Diagnostic and Prognostic Roles for T3/rT3 Ratio and T4

By MedXY|Aug 11, 2026

End-stage metabolic dysfunction-associated steatohepatitis (MASH) features profound disruptions in thyroid hormone metabolism across liver, portal, and systemic compartments, with the hepatic T3 level and systemic T3/rT3 ratio serving as se

Disentangling Weight Loss-Dependent and Independent Effects of Survodutide on Liver Outcomes in MASH: Insights from a Phase 2 Mediation Analysis
Diabetes & Endocrinology
MASH
Mediation Analysis

Disentangling Weight Loss-Dependent and Independent Effects of Survodutide on Liver Outcomes in MASH: Insights from a Phase 2 Mediation Analysis

By MedXY|Aug 4, 2026

This mediation analysis of a phase 2 MASH trial reveals that survodutide improves liver inflammation and fibrosis predominantly through weight-independent mechanisms, highlighting a potential direct hepatic effect beyond weight reduction.

Development and Validation of a Noninvasive Score for At-Risk Metabolic Dysfunction-Associated Steatohepatitis in Individuals with Obesity Undergoing Bariatric Surgery
Diabetes & Endocrinologybariatric surgeryliver disease

Development and Validation of a Noninvasive Score for At-Risk Metabolic Dysfunction-Associated Steatohepatitis in Individuals with Obesity Undergoing Bariatric Surgery

By MedXY|Jul 5, 2026

Researchers developed and validated the FMO score, a noninvasive, cost-effective tool to identify at-risk metabolic dysfunction-associated steatohepatitis (MASH) in obese patients, showing strong predictive performance across multiple inter

Lower-Dose Vitamin E Works as Well as Higher Doses in MASLD, VEDS Trial Finds
GastroenterologyALTMASH

Lower-Dose Vitamin E Works as Well as Higher Doses in MASLD, VEDS Trial Finds

By MedXY|Jun 19, 2026

In adults with suspected MASH, 200 IU/day vitamin E lowered ALT as effectively as 400 IU/day and 800 IU/day over 24 weeks, with no short-term safety signal, supporting lower-dose use if vitamin E is chosen.

Targeted Galectin-3 Inhibition for Portal Hypertension: Insights from the NAVIGATE Trial and Belapectin’s Role in MASH Cirrhosis
Clinical UpdatesBelapectincirrhosis

Targeted Galectin-3 Inhibition for Portal Hypertension: Insights from the NAVIGATE Trial and Belapectin’s Role in MASH Cirrhosis

By MedXY|Jun 1, 2026

This review synthesizes clinical evidence for Belapectin, a Galectin-3 inhibitor, focusing on its ability to prevent esophageal varices in patients with MASH cirrhosis and portal hypertension as demonstrated in the NAVIGATE trial.

Belapectin for the Prevention of Esophageal Varices in MASH Cirrhosis: Insights from the NAVIGATE Phase 2b Trial
Clinical UpdatesBelapectinEsophageal Varices

Belapectin for the Prevention of Esophageal Varices in MASH Cirrhosis: Insights from the NAVIGATE Phase 2b Trial

By MedXY|Jun 1, 2026

This review synthesizes clinical evidence on belapectin, a galectin-3 inhibitor, highlighting its potential to reduce the incidence of esophageal varices in patients with MASH-related cirrhosis and portal hypertension, particularly at the 2

Validating the Virtual Biopsy: Noninvasive Surrogate Endpoints for Disease Progression and Treatment Efficacy in MASH
Clinical Updatesliver fibrosisMASH

Validating the Virtual Biopsy: Noninvasive Surrogate Endpoints for Disease Progression and Treatment Efficacy in MASH

By MedXY|Apr 2, 2026

This review synthesizes the evolving landscape of noninvasive tests (NITs) in MASH, detailing their role as surrogate endpoints for adverse outcomes and therapeutic response based on recent clinical trials and meta-analyses.

Navigating the New Frontier of MASLD: An Updated Clinical Pathway for Liver Health
Diabetes & Endocrinologyclinical guidelinesHepatology

Navigating the New Frontier of MASLD: An Updated Clinical Pathway for Liver Health

By MedXY|Mar 13, 2026

This article summarizes the updated clinical care pathway for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), highlighting new diagnostic nomenclature, risk stratification tools, and the integration of the first FDA-approv

Monthly Efimosfermin Alfa Demonstrates Safety and Tolerability in MASH-Related Fibrosis: Insights from a Phase 2 Trial
Gastroenterologyefimosfermin alfaliver fibrosis

Monthly Efimosfermin Alfa Demonstrates Safety and Tolerability in MASH-Related Fibrosis: Insights from a Phase 2 Trial

By MedXY|Feb 16, 2026

The Phase 2 trial of efimosfermin alfa (BOS-580) shows that once-monthly dosing is safe and well-tolerated in patients with MASH and F2/F3 fibrosis, supporting its continued clinical development as a potential liver-targeted therapy.

Pemvidutide Demonstrates Robust MASH Resolution in IMPACT Phase 2b Trial: Clinical Implications of Dual GLP-1/Glucagon Agonism
Diabetes & EndocrinologyHepatologyMASH

Pemvidutide Demonstrates Robust MASH Resolution in IMPACT Phase 2b Trial: Clinical Implications of Dual GLP-1/Glucagon Agonism

By MedXY|Jan 14, 2026

The 24-week results of the IMPACT trial show that pemvidutide significantly improves MASH resolution without worsening fibrosis. While fibrosis improvement did not reach significance at this early time point, the drug’s safety profile

Dual Agonism for MASH: Pemvidutide Achieves Rapid Histological Resolution in Phase 2b IMPACT Trial
Diabetes & EndocrinologyMASHpemvidutide

Dual Agonism for MASH: Pemvidutide Achieves Rapid Histological Resolution in Phase 2b IMPACT Trial

By MedXY|Jan 13, 2026

The Phase 2b IMPACT trial demonstrates that pemvidutide, a GLP-1/glucagon dual agonist, significantly achieves MASH resolution at 24 weeks without dose titration, though fibrosis improvement did not reach significance at this early timepoin

Optimizing MASH Management: Synergistic Effects of Resmetirom, GLP-1 Receptor Agonists, and Weight Loss in the MAESTRO-NASH Secondary Analysis
Clinical Updatesclinical trialsGLP-1 RA

Optimizing MASH Management: Synergistic Effects of Resmetirom, GLP-1 Receptor Agonists, and Weight Loss in the MAESTRO-NASH Secondary Analysis

By MedXY|Jan 10, 2026

This review synthesizes findings from the MAESTRO-NASH trial, highlighting that Resmetirom’s efficacy is maintained alongside GLP-1 RAs and SGLT2 inhibitors, while being significantly enhanced by concurrent weight loss.

Tirzepatide and the Future of MASH Treatment: Insights from the SYNERGY-NASH Trial
Diabetes & Endocrinologyliver fibrosisMASH

Tirzepatide and the Future of MASH Treatment: Insights from the SYNERGY-NASH Trial

By MedXY|Jan 10, 2026

The SYNERGY-NASH trial demonstrates that Tirzepatide significantly improves MASH resolution and liver fibrosis. This effect is driven by substantial weight loss, improved glycemic control, and liver fat normalization, highlighting a transfo

Pemvidutide Produces Rapid Reductions in Liver Fat and AI‑Quantified Fibrosis in Early Phase Trials — Promise and Unanswered Questions
Diabetes & Endocrinologyliver fibrosisMASH

Pemvidutide Produces Rapid Reductions in Liver Fat and AI‑Quantified Fibrosis in Early Phase Trials — Promise and Unanswered Questions

By MedXY|Nov 14, 2025

Pemvidutide, a dual GLP‑1/glucagon receptor agonist, reduced liver fat markedly and produced small but statistically significant reductions in AI‑quantified fibrosis over 24 weeks in phase 2 studies, but longer trials with clinical endpoint

Standardizing Liver Biopsy Interpretation in MASH Trials: Key Consensus Statements from the International MASLD Pathology Group
Gastroenterologyliver biopsyMASH

Standardizing Liver Biopsy Interpretation in MASH Trials: Key Consensus Statements from the International MASLD Pathology Group

By MedXY|Oct 28, 2025

An evidence-based, practical summary of the IMPG consensus on standardized histologic grading and staging for MASH (MASLD) clinical trials, with recommendations for biopsy processing, feature definitions, scoring, central reading, and AI-re

Noninvasive Biomarkers Track Semaglutide Efficacy in Metabolic Dysfunction-Associated Steatohepatitis
Diabetes & Endocrinologybiomarkersliver fibrosis

Noninvasive Biomarkers Track Semaglutide Efficacy in Metabolic Dysfunction-Associated Steatohepatitis

By MedXY|Oct 9, 2025

A phase 2b trial demonstrates that several noninvasive tests reliably reflect treatment response to semaglutide in patients with metabolic dysfunction-associated steatohepatitis, correlating with histologic improvements over 72 weeks.

Rapirosiran: A Promising RNA Interference Therapy Targeting HSD17B13 for Metabolic Dysfunction-Associated Steatohepatitis
Clinical UpdatesHSD17B13MASH

Rapirosiran: A Promising RNA Interference Therapy Targeting HSD17B13 for Metabolic Dysfunction-Associated Steatohepatitis

By MedXY|Oct 8, 2025

This phase I randomized study shows rapirosiran, an RNAi therapeutic targeting HSD17B13, is safe and effectively reduces liver HSD17B13 mRNA in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Enhancing Fibrosis Scoring in MASH: The Role of AI-Enhanced Digital Pathology
AIclinical trialsfibrosis

Enhancing Fibrosis Scoring in MASH: The Role of AI-Enhanced Digital Pathology

By MedXY|Oct 8, 2025

AI-assisted digital pathology improves inter-pathologist agreement on fibrosis staging in metabolic dysfunction-associated steatohepatitis (MASH), enhancing clinical trial accuracy and efficiency.

AZD2693: Targeting PNPLA3 148M Variant as a Precision Therapy for Metabolic Steatohepatitis
Clinical UpdatesAntisense oligonucleotideMASH

AZD2693: Targeting PNPLA3 148M Variant as a Precision Therapy for Metabolic Steatohepatitis

By MedXY|Oct 8, 2025

AZD2693, a liver-directed antisense oligonucleotide, safely reduces PNPLA3 expression and liver fat in homozygous PNPLA3 148M carriers with metabolic dysfunction-associated steatohepatitis, signaling promise for precision treatment in this

Icosabutate in Metabolic Dysfunction-Associated Steatohepatitis: Insights from the Phase IIb ICONA Trial
Clinical UpdatesFFAR1FFAR4

Icosabutate in Metabolic Dysfunction-Associated Steatohepatitis: Insights from the Phase IIb ICONA Trial

By MedXY|Oct 8, 2025

A phase IIb trial of the FFAR1/FFAR4 agonist icosabutate in MASH shows encouraging fibrosis improvement and biomarker responses despite not meeting the primary endpoint, supporting further development.

1 / 2
12
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities